Another point of interest is that a percentage of people whom have contracted RRV apparently will eventually develop OA.
If treated with iPPS at an early point the inflammation subsides and the possibility of developing biomarkers should, based on data thus far be suppressed.
I know a friend from around Geelong (recent RRV breakout area) contracted RRV last November and has flare ups of pain in her joints frequently to which iPPS could and probably will be her saviour if she can access the SAS
Suppression of inflammation is the key to not developing other disease which in this case of RRV would likely be OA
Thanks Mozz for your welcoming remark and I was glued to that interview between Scott and Paul. Definitely another listen and have passed on to a few friends and family already.
Further, this forum has always been enquiring and welcoming views of difference and imo the only exclusion are people who have no conviction and an agenda to provoke.
All the best to PAR and investors
- Forums
- ASX - By Stock
- PAR
- Ann: PHASE 2 RRV DATA PUBBLISHED IN PEER-REVIEWED JOURNAL
Ann: PHASE 2 RRV DATA PUBBLISHED IN PEER-REVIEWED JOURNAL, page-24
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
30.5¢ |
Change
0.005(1.67%) |
Mkt cap ! $106.6M |
Open | High | Low | Value | Volume |
30.5¢ | 31.5¢ | 29.5¢ | $152.7K | 501.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 16864 | 30.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 20426 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 16864 | 0.305 |
1 | 62640 | 0.300 |
4 | 99959 | 0.295 |
5 | 18241 | 0.290 |
3 | 51043 | 0.285 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 20426 | 2 |
0.320 | 55000 | 2 |
0.325 | 50366 | 4 |
0.330 | 56660 | 4 |
0.335 | 13500 | 2 |
Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |